Pancreatic Cancer Research

ResearcherFred Hutch Cancer CenterActive in the last 2 years

Jason B. Fleming

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-8796-5627; OpenAlex author ID A5037694904, A5151982779; NIH RePORTER profile ID 7391237. Sources: ClinicalTrials.gov.

Their work

Papers
171 (first author 6, last author 35)
Trials
1 (principal investigator on 1)
Grants
2
Labs led
3
Collaborators
409
Papers, trials and grants by year

2008: 1 trial · 2009: none · 2010: none · 2011: 6 papers · 2012: 21 papers · 2013: 9 papers · 2014: 13 papers · 2015: 14 papers · 2016: 17 papers · 2017: 17 papers · 2018: 9 papers · 2019: 18 papers · 2020: 6 papers, 1 grant · 2021: 12 papers · 2022: 8 papers, 1 grant · 2023: 6 papers · 2024: 6 papers · 2025: 4 papers · 2026: 5 papers

Papers 50 of 171

  1. Ratiometric Fluorescent Chemosensing for Predicting Response to Irinotecan-Based Therapies in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1021/acssensors.5c04552↗
  2. Author Correction: Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Co-author DOI 10.1038/s41586-026-10488-6↗
  3. Author Correction: Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer. Co-author DOI 10.1038/s41586-026-10995-6↗
  4. Author Correction: Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer. Co-author DOI 10.1038/s41586-026-11134-x↗
  5. The impact of neighborhood socioeconomic deprivation on metastatic pancreatic cancer treatment and survival: An incidence-based, causally-structured observatio… Co-author DOI 10.64898/2026.08.06.26359821↗
  6. Race-based differences in serum biomarkers for cancer-associated cachexia in a diverse cohort of patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s43856-025-01277-9↗
  7. SMAD4 Deficiency Promotes Pancreatic Cancer Progression and Confers Susceptibility to TGFβ Inhibition. Co-author DOI 10.1158/0008-5472.can-24-1970↗
  8. The Impact of Edema on Skeletal Muscle Changes among Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1055-9965.epi-25-0237↗
  9. Association of Pathologic Response and Adjuvant Chemotherapy with Survival in Resected Pancreatic Ductal Adenocarcinoma Following Neoadjuvant Therapy. Co-author DOI 10.3390/cancers17111797↗
  10. Surgery for Borderline Resectable Pancreatic Ductal Adenocarcinoma: Preoperative Planning, Technical Considerations, and Building a Program. Co-author DOI 10.1016/j.suc.2024.07.001↗
  11. Retraction Note: Hypoxia-induced autophagy of stellate cells inhibits expression and secretion of lumican into microenvironment of pancreatic ductal adenocarci… Last author DOI 10.1038/s41418-024-01387-2↗
  12. Nardilysin-regulated scission mechanism activates polo-like kinase 3 to suppress the development of pancreatic cancer. Co-author DOI 10.1038/s41467-024-47242-3↗
  13. Editor's Note: Ex Vivo Testing of Patient-Derived Xenografts Mirrors the Clinical Outcome of Patients with Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1158/1078-0432.ccr-24-1527↗
  14. Correction: Real time ex vivo chemosensitivity assay for pancreatic adenocarcinoma. Last author DOI 10.18632/oncotarget.28556↗
  15. Leveraging real-world data to predict cancer cachexia stage, quality of life, and survival in a racially and ethnically diverse multi-institutional cohort of t… Co-author DOI 10.3389/fonc.2024.1362244↗
  16. The impact of age and comorbidity on localized pancreatic cancer outcomes: A US retrospective cohort analysis with implications for surgical centralization. Co-author DOI 10.1016/j.sopen.2023.02.001↗
  17. RBFOX2 deregulation promotes pancreatic cancer progression and metastasis through alternative splicing. Co-author DOI 10.1038/s41467-023-44126-w↗
  18. Management of Patients With Pancreatic Cancer Using the "Right Track" Model. Last author DOI 10.1093/oncolo/oyad080↗
  19. Discovery of KRB-456, a KRAS G12D Switch-I/II Allosteric Pocket Binder That Inhibits the Growth of Pancreatic Cancer Patient-derived Tumors. Co-author DOI 10.1158/2767-9764.crc-23-0222↗
  20. Multi-Institutional Outcomes of Patients Aged 75 years and Older With Pancreatic Ductal Adenocarcinoma Treated With 5-Fraction Ablative Stereotactic Magnetic R… Co-author DOI 10.1177/10732748221150228↗
  21. Real time ex vivo chemosensitivity assay for pancreatic adenocarcinoma. Last author DOI 10.18632/oncotarget.28508↗
  22. Surgical approach to pancreaticoduodenectomy for pancreatic adenocarcinoma: uncomplicated ends justify the means. Co-author DOI 10.1007/s00464-021-08845-9↗
  23. Patient-caregiver dyads in pancreatic cancer: identification of patient and caregiver factors associated with caregiver well-being. Co-author DOI 10.1007/s10865-022-00354-x↗
  24. Adjuvant Chemoradiotherapy in Resected Pancreatic Ductal Adenocarcinoma: Where Does the Benefit Lie? A Nomogram for Risk Stratification and Patient Selection. Co-author DOI 10.1007/s11605-021-05130-x↗
  25. Surgical and Pathologic Outcomes of Pancreatic Adenocarcinoma (PA) After Preoperative Ablative Stereotactic Magnetic Resonance Image Guided Adaptive Radiation … Co-author DOI 10.1016/j.adro.2022.101045↗
  26. A comparative Proteomics Analysis Identified Differentially Expressed Proteins in Pancreatic Cancer-Associated Stellate Cell Small Extracellular Vesicles. Co-author DOI 10.1016/j.mcpro.2022.100438↗
  27. CES2 sustains HNF4α expression to promote pancreatic adenocarcinoma progression through an epoxide hydrolase-dependent regulatory loop. Co-author DOI 10.1016/j.molmet.2021.101426↗
  28. Hospital Surgical Volume Is Poorly Correlated With Delivery of Multimodal Treatment for Localized Pancreatic Cancer: A National Retrospective Cohort Study. Last author DOI 10.1097/as9.0000000000000197↗
  29. 3D imaging analysis on an organoid-based platform guides personalized treatment in pancreatic ductal adenocarcinoma. Co-author DOI 10.1172/jci151604↗
  30. IGFBP2 promotes tumor progression by inducing alternative polarization of macrophages in pancreatic ductal adenocarcinoma through the STAT3 pathway. Co-author DOI 10.1016/j.canlet.2020.12.008↗
  31. Compound NSC84167 selectively targets NRF2-activated pancreatic cancer by inhibiting asparagine synthesis pathway. Last author DOI 10.1038/s41419-021-03970-8↗
  32. PRMT1-dependent regulation of RNA metabolism and DNA damage response sustains pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41467-021-24798-y↗
  33. APOBEC3A drives deaminase domain-independent chromosomal instability to promote pancreatic cancer metastasis. Co-author DOI 10.1038/s43018-021-00268-8↗
  34. The Impact of Socioeconomic Deprivation on Clinical Outcomes for Pancreatic Adenocarcinoma at a High-volume Cancer Center: A Retrospective Cohort Analysis. Last author DOI 10.1097/sla.0000000000003706↗
  35. Targeting Glucose Metabolism Sensitizes Pancreatic Cancer to MEK Inhibition. Co-author DOI 10.1158/0008-5472.can-20-3792↗
  36. Global Phosphoproteomics Reveal CDK Suppression as a Vulnerability to KRas Addiction in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-20-4781↗
  37. Oncogenic KRAS Recruits an Expansive Transcriptional Network through Mutant p53 to Drive Pancreatic Cancer Metastasis. Co-author DOI 10.1158/2159-8290.cd-20-1228↗
  38. DDR1-induced neutrophil extracellular traps drive pancreatic cancer metastasis. Last author DOI 10.1172/jci.insight.146133↗
  39. Value of Neoadjuvant Radiation Therapy in the Management of Pancreatic Adenocarcinoma. Co-author DOI 10.1200/jco.21.01220↗
  40. Identification of Targetable Gene Fusions and Structural Rearrangements to Foster Precision Medicine in KRAS Wild-Type Pancreatic Cancer. Co-author DOI 10.1200/po.20.00265↗
  41. The Florida Pancreas Collaborative Next-Generation Biobank: Infrastructure to Reduce Disparities and Improve Survival for a Diverse Cohort of Patients with Pan… Co-author DOI 10.3390/cancers13040809↗
  42. Cancer outcomes are independent of preoperative CA 19-9 in anatomically resectable pancreatic ductal adenocarcinoma: A retrospective cohort analysis. Co-author DOI 10.1002/jso.26103↗
  43. White paper on pancreatic ductal adenocarcinoma from society of abdominal radiology's disease-focused panel for pancreatic ductal adenocarcinoma: Part I, AJCC … Co-author DOI 10.1007/s00261-019-02289-5↗
  44. White paper on pancreatic ductal adenocarcinoma from society of abdominal radiology's disease-focused panel for pancreatic ductal adenocarcinoma: Part II, upda… Co-author DOI 10.1007/s00261-019-02290-y↗
  45. Completion of adjuvant therapy in patients with resected pancreatic cancer. Last author DOI 10.1016/j.hpb.2019.07.008↗
  46. Neutrophil to lymphocyte ratio, not platelet to lymphocyte or lymphocyte to monocyte ratio, is predictive of patient survival after resection of early-stage pa… Co-author DOI 10.1186/s12885-020-07182-9↗
  47. CES2 Expression in Pancreatic Adenocarcinoma Is Predictive of Response to Irinotecan and Is Associated With Type 2 Diabetes. Co-author DOI 10.1200/po.19.00330↗
  48. Racial and ethnic disparities in a state-wide registry of patients with pancreatic cancer and an exploratory investigation of cancer cachexia as a contributor … Co-author DOI 10.1002/cam4.2180↗
  49. Clinical candidate and genistein analogue AXP107-11 has chemoenhancing functions in pancreatic adenocarcinoma through G protein-coupled estrogen receptor signa… Co-author DOI 10.1002/cam4.2581↗
  50. Physical activity and exercise during preoperative pancreatic cancer treatment. Co-author DOI 10.1007/s00520-018-4493-6↗

Trials 1

  1. Preoperative Chemotherapy (Gemcitabine and Erlotinib) With or Without Radiation Therapy Principal investigator NCT00766636↗

Grants 2

  1. Project 2: Building Combinatorial Therapies against KRAS-mutant Colorectal and Pancreatic Cancer U54CA224065↗
  2. Transport of Effector T cells and Nano-DC vaccine in Breast Cancer U54CA210181↗

Closest collaborators

The 25 strongest of 409 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ya’an Kang · 50 shared papers, 2012–2026 · strength 4.08
  2. Matthew H. G. Katz · 79 shared papers, 2011–2022 · strength 3.79
  3. Huamin Wang · 60 shared papers, 2011–2026 · strength 3.40
  4. Anirban Maitra · 36 shared papers, 2014–2026 · strength 2.64
  5. Mokenge Peter Malafa · 18 shared papers, 2020–2025 · strength 2.59
  6. Jeffrey E. Lee · 52 shared papers, 2011–2022 · strength 2.35
  7. Pamela Joy Hodul · 16 shared papers, 2019–2025 · strength 2.30
  8. Jason W. Denbo · 15 shared papers, 2016–2025 · strength 2.27
  9. Michael P. Kim · 23 shared papers, 2011–2024 · strength 1.82
  10. Gauri Rajani Varadhachary · 42 shared papers, 2011–2019 · strength 1.78
  11. Robert A. Wolff · 40 shared papers, 2011–2022 · strength 1.72
  12. Eugene Jon Koay · 23 shared papers, 2014–2024 · strength 1.68
  13. Jennifer B. Permuth · 10 shared papers, 2019–2026 · strength 1.66
  14. Xinqun Li · 14 shared papers, 2014–2024 · strength 1.51
  15. Bingbing Dai · 15 shared papers, 2015–2024 · strength 1.37
  16. José M. Pimiento · 9 shared papers, 2020–2025 · strength 1.27
  17. Mayrim V. Rios Perez · 13 shared papers, 2015–2024 · strength 1.26
  18. Haoqiang Ying · 14 shared papers, 2013–2026 · strength 1.23
  19. David Roife · 14 shared papers, 2014–2024 · strength 1.20
  20. Daniel A. Anaya · 6 shared papers, 2021–2026 · strength 1.16
  21. Benjamin Daniel Powers · 8 shared papers, 2019–2026 · strength 1.10
  22. Christopher H. Crane · 26 shared papers, 2011–2021 · strength 1.07
  23. Giulio Francesco Draetta · 12 shared papers, 2014–2026 · strength 1.07
  24. Timothy Paul Heffernan · 12 shared papers, 2014–2026 · strength 1.00
  25. Ronald Anthony Depinho · 11 shared papers, 2013–2026 · strength 0.99

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.